Stevenage 21st March 2022 – Autifony CEO Charles Large will be speaking in the Pharmaceutical Pipeline session at this year’s SIRS conference in Florence, Italy. Dr Large will present new…
Read More
Autifony CEO Charles Large will be speaking at the webinar ‘Fragile X syndrome – in pursuit of a cure’ World Fragile X Day, Thurs 22 July 2021 – Full webinar…
Read More
Stevenage 16th April – This weekend Dr Charles Large will present key biomarker efficacy data from a first study of AUT00206 in patients with schizophrenia to the Schizophrenia International Research…
Read More
Stevenage, UK – 04 March 2021 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious nervous system disorders, including schizophrenia, hearing loss, Fragile…
Read More
